MCL Therapy Selection and Sequencing

Panelists discuss the treatment- and patient-specific factors considered when determining induction therapy for treatment-naive patients with mantle cell lymphoma (MCL), including the decision between aggressive and less aggressive approaches, and how prior therapy exposure influences subsequent treatment sequencing for MCL.

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP: 4.Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP: 5.Future Directions and Research Priorities in BTKi Treatment Approaches

EP: 6.Latest Trends and Innovations in CLL and MCL Treatment

EP: 7.CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP: 8.Navigating CLL Treatment Choices

EP: 9.Therapy Sequencing in CLL

EP: 10.MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

Now Viewing

EP: 11.MCL Therapy Selection and Sequencing

EP: 12.Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

EP: 13.Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

EP: 14.Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL

EP: 15.Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences

EP: 16.Implementation of Shared Decision-Making in BTK Inhibitor Treatment

EP: 17.Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence

EP: 18.Future Directions and Overcoming Challenges in BTK Inhibitor Therapy

EP: 19.Impact of Access Challenges on Patient Outcomes in CLL and MCL Care

EP: 20.Balancing Clinical Benefits and Costs of BTK Inhibitors

EP: 21.Inflation Reduction Act: Impact on Health Care Systems’ Utilization of BTK Inhibitors

EP: 22.Inflation Reduction Act: Impact on Affordability of BTK Inhibitors

1. What treatment- and patient-specific factors do you consider when determining induction therapy for a treatment-naive patient with MCL (eg, aggressive vs less aggressive)?
2. How do you sequence therapies for patients with MCL and how does prior therapy exposure influence your subsequent choice of treatments?

Related Videos